Quest Diagnostics Guides FY23 Adj. EPS In Line With Estimates - Update
(RTTNews) - While reporting financial results for the fourth quarter on Thursday, Quest Diagnostics Inc. (DGX) initiated its earnings, adjusted earnings and revenue guidance for the full-year 2023.
For fiscal 2023, the company now projects earnings in a range of $7.61 and $8.21 per share and adjusted earnings in a range of $8.40 and $9.00 per share on net revenues between $8.83 billion and $9.03 billion.
On average, 16 analysts polled by Thomson Reuters expect the company to report earnings of $8.69 per share on revenues of $9.13 billion for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
read more
Haystack Oncology And Lisata Therapeutics Partner To Evaluate Efficacy Of Pancreatic Cancer Therapy
Haystack Oncology, a Quest Diagnostics (DGX) company, and Lisata Therapeutics, Inc. (LSTA), a clinical-stage pharmaceutical company, announced Thursday a research collaboration to use the Haystack MRD Technology to evaluate efficacy of Pancreatic Cancer Therapy.
RTTNews
|
103天前
Quest Diagnostics To Acquire Outreach Laboratory Services Of OhioHealth
Quest Diagnostics (DGX), a provider of diagnostic information services, and OhioHealth, a nationally recognized not-for-profit, charitable, integrated health system, announced Wednesday a definitive agreement for Quest to acquire select assets of OhioHealth's outreach laboratory services business.
RTTNews
|
111天前
Quest Diagnostics To Acquire LifeLabs From OMERS In About $985 Mln Deal
Quest Diagnostics (DGX), a provider of diagnostic information services, announced Wednesday a definitive agreement to acquire LifeLabs, a provider of community laboratory tests for millions of Canadians, from OMERS for a value of approximately C$1.35 billion (approximately $985 million), including net debt.
RTTNews
|
118天前
Quest Diagnostics Awarded Contract To Assess Burden Of Hepatitis C Virus In U.S By CDC
Quest Diagnostics (DGX), a leading provider of hepatitis testing services, announced Thursday it has been awarded a contract by the U.S. Centers for Disease Control and Prevention (CDC) designed to assess the burden of hepatitis C virus (HCV) in the U.S.
RTTNews
|
327天前
Quest, Scipher Team Up To Expand Diagnostic Services Access For Patients With Rheumatoid Arthritis
Diagnostic services provider Quest Diagnostics (DGX) and precision immunology company Scipher Medicine announced Tuesday a multi-pronged collaboration designed to expand patient access to diagnostic services advancing precision medicine for rheumatoid arthritis (RA).
RTTNews
|
336天前
Quest Diagnostics Narrows FY23 Adj. EPS Outlook Range, Boosts Revenue Forecast - Update
While reporting financial results for the third quarter on Wednesday, Quest Diagnostics Inc. (DGX) narrowed its earnings and adjusted earnings guidance range for the full-year 2023, while raising annual revenue outlook.
RTTNews
|
371天前
Quest Diagnostics Says FDA Grants Breakthrough Designation For Adeno-associated Virus Test
Quest Diagnostics (DGX), a diagnostic information services provider, announced Wednesday that its AAVrh74 ELISA assay (CDx) has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).
RTTNews
|
426天前
Quest Diagnostics Boosts FY23 Adj. EPS, Revenue Outlook - Update
While reporting financial results for the second quarter on Wednesday, Quest Diagnostics Inc. (DGX) raised its adjusted earnings and revenue guidance for the full-year 2023.
RTTNews
|
461天前
